Genitourinary Cancers | Specialty

Dr. Campbell on the Impact of the COVID-19 Pandemic in RCC

January 8th 2021

Matthew T. Campbell, MD, MS, discusses the impact of the coronavirus disease 2019 pandemic in renal cell carcinoma.

More Innovation Is on Tap for 2021: Five Experts Describe Key Trends

January 8th 2021

The development of additional molecularly targeted therapies and the search for enhanced immunotherapy regimens are expected to permeate the oncology landscape across a broad range of malignancies as 2021 unfolds.

Hussain and Taplin Talk Gender-Specific Struggles, Career Lessons in GU Oncology

January 8th 2021

Maha H.A. Hussain, MD, and Mary-Ellen Taplin, MD, sit down with OncLive® to travel the road that led them to specialize in genitourinary oncology, the challenges they experienced as a female in the field, and advice they would give to not only other rising female oncologists, but to their younger selves knowing what they know now.

Dr. Grigg on the Results of the CheckMate-214 Trial in RCC

January 7th 2021

Claud M. Grigg, Jr., MD, discusses the results of the CheckMate-214 trial in renal cell carcinoma.

Eganelisib/Nivolumab Elicits Promising Responses, PFS Benefit in Metastatic Urothelial Cancer

January 7th 2021

January 7th, 2021 - The addition of eganelisib to nivolumab was found to elicit encouraging responses and improve progression-free survival compared with single-agent nivolumab in patients with platinum-refractory, immunotherapy-naïve, advanced, metastatic urothelial cancer.

Dr. McGregor on the Focus of Future Research Efforts in RCC

January 7th 2021

Bradley McGregor, MD, discusses the focus of future research efforts in renal cell carcinoma.

Dr. Gupta on Developing Biomarkers of Lack of Response in Urothelial Carcinoma

January 5th 2021

Shilpa Gupta, MD, discusses the need to develop biomarkers of lack of response to immunotherapy in urothelial carcinoma.

Telaglenastat Plus Cabozantinib Fails to Improve PFS in Advanced or Metastatic RCC

January 4th 2021

The combination of telaglenastat plus cabozantinib failed to result in a significant improvement in progression-free survival in patients with advanced or metastatic renal cell carcinoma.

Expert Compares Open vs Robotic Radical Cystectomy Approaches in Muscle Invasive Bladder Cancer

January 2nd 2021

Bryon Lee, MD, PhD, discusses recent advances in surgical technique, approach, and perioperative care have made radical cystectomy significantly less morbid for patients with muscle invasive bladder cancer.

Mian Makes Sense of Multidisciplinary Bladder Preservation Approaches

December 31st 2020

Omar Mian, MD, PhD, discusses selective bladder preservation in patients with muscle-invasive bladder cancer, biomarkers of response, and the utilization of hypofractionated radiation vs traditional approaches in this population.